Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.51 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9594133 | 0.98 | HSD17B10 (0.58) | HSD17B10KMT2AMEN1RAB9APDK1 | |
| SCHEMBL3273626 | 0.85 | HSD17B10 (0.60) | HSD17B10KMT2AMEN1RAB9ACA1 | |
| Hydrochloric Acid SCHEMBL1118002 | 0.84 | HSD17B10 (0.58) | HSD17B10KMT2AMEN1RAB9ACA1 | |
| SCHEMBL4361693 | 0.81 | HSD17B10 (0.60) | HSD17B10KMT2AMEN1RAB9APDK1 | |
| SCHEMBL29036913 | 0.80 | HSD17B10 (0.58) | HSD17B10KMT2AMEN1RAB9APDK1 | |
| SCHEMBL27910937 | 0.80 | KMT2A (0.63) | KMT2AMEN1RAB9APDK1PDK2 | |
| SCHEMBL9387603 | 0.79 | TDP1 (0.55) | HSD17B10KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL29702896 | 0.79 | TDP1 (0.55) | HSD17B10KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL5462968 | 0.79 | HSD17B10 (0.56) | HSD17B10KMT2AMEN1RAB9APDK1 | |
| SCHEMBL5462964 | 0.79 | HSD17B10 (0.56) | HSD17B10KMT2AMEN1RAB9APDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4285906-A2 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme Inc (US) | 2023-12-06 | — | — | EP | disclosed |
| EP-3555070-B1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | EPIZYME INC (US) | 2023-08-09 | — | — | EP | disclosed |
| CN-116041346-A | Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof | EPIZYME股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-110088099-B | Amine-substituted heterocyclic compounds as EHMT2 inhibitors and methods of use thereof | EPIZYME股份有限公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20220235065-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2022-07-28 | — | — | US | disclosed |
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2020-02-06 | — | — | US | disclosed |
| EP-3555070-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme Inc (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2018118842-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2018-06-28 | — | — | WO | disclosed |
| US-5436259-A | Angiotensive II antagonist as hypotensive agents | MERCK & CO., INC. (US) | 1995-07-25 | — | — | US | disclosed |
| US-5411980-A | Substituted triazolinones, triazolinethiones, and triazolinimines as angiotensin II antagonists | MERCK & CO., INC. (US) | 1995-05-02 | — | — | US | disclosed |
| EP-0258773-B1 | Benzothiazolones, their production and use as herbicides | SUMITOMO CHEMICAL CO (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0586513-A1 | ACIDIC ARALKYL TRIAZOLE DERIVATIVES ACTIVE AS ANGIOTENSIN II ANTAGONISTS | MERCK & CO. INC. (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5281614-A | Hypotensive agents, glaucoma or angiotensin antagonists | MERCK & CO., INC. (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0526001-A1 | Substituted triazolinones | MERCK & CO. INC. (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1993001177-A1 | SUBSTITUTED TRIAZOLINONES | MERCK & CO., INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| WO-1992020662-A1 | ACIDIC ARALKYL TRIAZOLE DERIVATIVES ACTIVE AS ANGIOTENSIN II ANTAGONISTS | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| US-4912225-A | From a 1,3,4-oxadiazol-2-one compound with a halogenated phenyl compound in position 3 | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-03-27 | — | — | US | disclosed |
| US-4824465-A | HERBICIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-04-25 | — | — | US | disclosed |
| EP-0258773-A2 | Benzothiazolones, their production and use as herbicides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220235065-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | HNMT, BHMT, EHMT2 | HSD17B10 582/4885KMT2A 28/4885MEN1 842/4885 |
| US-20200039998-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND METHODS OF USE THEREOF | HNMT, BHMT, EHMT2 | HSD17B10 540/4885KMT2A 28/4885MEN1 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.